About
Titles
Hospital Resident
Biography
Hometown: Kingsville, TX
Medical School: University of California San Francisco
Undergraduate: Harvard College
Professional Interests: Surgical oncology, Healthcare Economics, Global Health, Health Disparities, Medical device/diagnostics.
Hobbies: Ballroom Dancing, Basketball, Running, Playing Piano
Education & Training
- MD
- University of California San Francisco (2020)
- AB
- Harvard College, Chemical and Physical Biology (2014)
Research
Overview
Medical Research Interests
Artificial Intelligence; Consensus; Cytoreduction Surgical Procedures; Liver; Melanoma, Cutaneous Malignant; Neuroendocrine Tumors; Spatial Analysis; Surgical Oncology; Translational Science, Biomedical
Public Health Interests
Global Health
ORCID
0000-0002-8693-612X
Research at a Glance
Yale Co-Authors
Frequent collaborators of David Su's published research.
Publications Timeline
A big-picture view of David Su's research output by year.
Research Interests
Research topics David Su is interested in exploring.
Harriet Kluger, MD
David Schoenfeld, MD, PhD
Dijana Djureinovic, PhD, MSc
Kelly Olino, MD, FACS
Lucia Jilaveanu, MD, PhD
Kiran Turaga, MD, MPH
18Publications
120Citations
Cytoreduction Surgical Procedures
Publications
2025
SIMVI disentangles intrinsic and spatial-induced cellular states in spatial omics data
Dong M, Su D, Kluger H, Fan R, Kluger Y. SIMVI disentangles intrinsic and spatial-induced cellular states in spatial omics data. Nature Communications 2025, 16: 2990. PMID: 40148341, PMCID: PMC11950362, DOI: 10.1038/s41467-025-58089-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOmics dataSpatial omics dataAnalysis of gene expressionSingle-cell resolutionDownstream analysisCellular statesSpatial interaction modelsGerminal center B cellsGene expressionCommunication machineryOmics technologiesIntercellular interactionsSpatial omics technologiesTumor microenvironmentB cellsSpatial dynamicsHuman tonsilsMacrophage stateSpatial effectsReal-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma
Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.Peer-Reviewed Original ResearchConceptsMerkel cell carcinomaMerkel cell carcinoma casesT-VECCell carcinomaMedian numberAnti-PD-1 blockadeStage IIIB-IV melanomaAdvanced Merkel cell carcinomaIn-transit melanomaIn-transit diseaseICI therapyTalimogene laherparepvecAdvanced melanomaCancer immunotherapyMetastatic sitesPartial responseIn-transitRegional metastasesMedian ageGrade 3Adverse eventsTreatment cyclesDisease progressionMelanomaPatients
2024
Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma
Schoenfeld D, Djureinovic D, Su D, Zhang L, Lu B, Kamga L, Mann J, Huck J, Hurwitz M, Braun D, Jilaveanu L, Ring A, Kluger H. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight 2024, 10: e184545. PMID: 39561007, PMCID: PMC11721305, DOI: 10.1172/jci.insight.184545.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAnti-CTLA-4Renal cell carcinomaIL-18IL-18BPCell carcinomaTumor microenvironmentTumor typesPatients treated with immune checkpoint inhibitorsRegulatory T cell levelsAnti-PD-1 treatmentCD8+ T cellsAnti-PD-1Immune checkpoint inhibitorsCell renal cell carcinomaNon-responder patientsMyeloid cell populationsT cell levelsCytokine interleukin-18Anti-cancer efficacySecreted binding proteinCheckpoint inhibitorsResponding patientsPreclinical modelsT cellsMurine modelWhen Benchmarks Fail Us: A Case Study in Cytoreductive Surgery
Bansal V, Witmer H, Childers C, Su D, Turaga K. When Benchmarks Fail Us: A Case Study in Cytoreductive Surgery. Annals Of Surgical Oncology 2024, 32: 19-23. PMID: 39460818, DOI: 10.1245/s10434-024-16191-y.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsMutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy
Su D, Dhiman A, Bansal V, Zha Y, Shergill A, Polite B, Alpert L, Turaga K, Eng O. Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy. JCO Precision Oncology 2024, 8: e2400149. PMID: 39259912, PMCID: PMC11432692, DOI: 10.1200/po.24.00149.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHigh-grade appendiceal adenocarcinomaHyperthermic intraperitoneal chemotherapyProgression-free survivalImmunogenomic profilingAppendiceal cancerIntraperitoneal chemotherapyPeritoneal metastasisHigh-grade appendiceal cancerCD8<sup>+</sup> T cellsCytotoxic T cell populationsMutational signaturesAssociated with poor survivalElevated PD-L1Median overall survivalPD-L1 coexpressionPeritoneal tumour depositsT cell populationsTumor microenvironment alterationsNovel treatment approachesWhole-exome sequencingHIPEC treatmentAppendiceal adenocarcinomaOncological outcomesPD-L1Overall survivalTIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRenal cell carcinomaRenal cell carcinoma tumorsT cellsTIGIT expressionCheckpoint inhibitorsPD-1Likelihood of response to therapyTumor-infiltrating T cellsCD3+ T cellsRenal cell carcinoma metastasisTreatment of renal cell carcinomaImmune checkpoint inhibitorsInfiltrating T cellsPurposeImmune checkpoint inhibitorsResponse to therapyT cell immunoglobulinCD3+ levelsMetastatic RCC specimensAdjacent normal renal tissuesNormal renal tissuesQuantitative immunofluorescence analysisCell carcinomaResistant diseasePotential therapeutic targetTissue microarrayGP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsGp100 expressionCutaneous melanomaTreatment of cutaneous melanomaAdvanced cutaneous melanomaT-cell engagersImprove patient selectionMetastatic melanomaUveal melanomaMetastatic samplesPatient selectionClinical trialsMelanomaQuantitative immunofluorescence methodGp100Improve outcomesImmunofluorescence methodTherapeutic intentDrugCellular productsExpressionTebentafuspImmunohistochemistrySurgical Outcomes and Utilization of Laparoscopic Versus Robotic Techniques for Elective Colectomy in Asian American and Native Hawaiian-Pacific Islanders (AAPI) Diagnosed With Colon Cancer
Ahuja V, Murthy S, Leeds I, Paredes L, Su D, Tsutsumi A, Perkal M, King J. Surgical Outcomes and Utilization of Laparoscopic Versus Robotic Techniques for Elective Colectomy in Asian American and Native Hawaiian-Pacific Islanders (AAPI) Diagnosed With Colon Cancer. Journal Of Surgical Research 2024, 302: 40-46. PMID: 39083904, DOI: 10.1016/j.jss.2024.07.007.Peer-Reviewed Original ResearchConceptsLaparoscopic colectomyRobotic colectomyAAPI patientsColorectal cancerLength of stayClinical outcomesNative Hawaiian Pacific IslanderAmerican College of Surgeons National Surgical Quality Improvement Program databaseSurgeons National Surgical Quality Improvement Program databaseNational Surgical Quality Improvement Program databaseOperative timeQuality Improvement Program databaseMultivariate logistic regression analysisMean operative timeColorectal cancer resectionOutcomes of LCMinimally invasive approachMultivariate logistic regressionStandard of careLogistic regression analysisElective RCElective LCAnastomotic leakElective colectomySurgical outcomesOutcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation
Su D, Rehman S, Wang K, Deng Y, Rose M, Dosani T, Kunstman J. Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation. Journal Of Surgical Research 2024, 301: 10-17. PMID: 38905768, DOI: 10.1016/j.jss.2024.04.033.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHematology consultationSingle-center retrospective studyClavien-Dindo classificationVA Connecticut Healthcare SystemAssess operative outcomesTime to resolutionPrimary outcome measureE-consultationOperative morbidityPostoperative transfusionHematologic complicationsSurgical outcomesNo significant differenceRetrospective studyProcedural dataOperative outcomesProcedural outcomesStudy cohortPatient characteristicsConsult volumeSecondary outcomesHematologic issuesAssociated with changesReferral patternsSurgeryMulti-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers
Belmont E, Bansal V, Yousef M, Zeineddine M, Su D, Dhiman A, Liao C, Polite B, Eng O, Fournier K, White M, Turaga K, Shen J, Shergill A. Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precision Oncology 2024, 8: e2300531. PMID: 38723230, DOI: 10.1200/po.23.00531.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCirculating tumor DNAComplete cytoreductive surgeryCirculating tumor DNA detectionAppendiceal cancerPeritoneal metastasisGrade 2Systemic therapyTumor DNAComplete CRSAssociated with shorter recurrence-free survivalCirculating tumor DNA testingShorter recurrence-free survivalSystemic therapy responseRecurrence-free survivalDiagnosis of recurrenceDetection of recurrenceMulti-institutional studyCytoreductive surgerySystemic chemotherapyCA19-9Elevated biomarkersTherapy responseCtDNA detectionSpecialized centersCarcinoembryonic antigen
News
News
- March 24, 2025
Yale Surgeons to Present at International Surgical Oncology Conference
- November 04, 2022
Albertus Magnus Cancer Research Student Science Day
Get In Touch
Contacts
Email